HighVista Strategies LLC Purchases 12,899 Shares of Keros Therapeutics, Inc.
KROS Stock | USD 16.42 0.39 2.32% |
Slightly above 56% of Keros Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Keros Therapeutics suggests that many traders are alarmed. Keros Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Keros Therapeutics' earnings reports, geopolitical events, and overall market trends.
Keros |
HighVista Strategies LLC boosted its position in Keros Therapeutics, Inc. by 32.9 percent during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,107 shares of the companys stock after buying an additional 12,899 shares during the quarter. Keros Therapeutics makes up
Read at thelincolnianonline.com
Keros Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Keros Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Keros Therapeutics Fundamental Analysis
We analyze Keros Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Keros Therapeutics is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Keros Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Keros Therapeutics stock to make a market-neutral strategy. Peer analysis of Keros Therapeutics could also be used in its relative valuation, which is a method of valuing Keros Therapeutics by comparing valuation metrics with similar companies.
Peers
Keros Therapeutics Related Equities
BOLT | Bolt Biotherapeutics | 1.96 | ||||
MGTX | MeiraGTx Holdings | 1.64 | ||||
AVTE | Aerovate Therapeutics | 1.52 | ||||
MLYS | Mineralys Therapeutics, | 0.39 | ||||
LRMR | Larimar Therapeutics | 1.00 | ||||
SNDX | Syndax Pharmaceuticals | 1.24 | ||||
HRMY | Harmony Biosciences | 1.50 | ||||
JANX | Janux Therapeutics | 1.94 | ||||
GLUE | Monte Rosa | 2.22 | ||||
FENC | Fennec Pharmaceuticals | 2.35 | ||||
IDYA | Ideaya Biosciences | 2.71 | ||||
KZR | Kezar Life | 2.92 | ||||
ERAS | Erasca | 3.05 | ||||
EWTX | Edgewise Therapeutics | 3.10 | ||||
IPSC | Century Therapeutics | 3.70 | ||||
REPL | Replimune | 4.14 | ||||
ANAB | AnaptysBio | 5.09 | ||||
SRZN | Surrozen | 5.95 |
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.